Pharmamarketeer

Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo

MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in...

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.

Allergan’s acute migraine therapy ubrogepant shows strength at Phase 3

Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s strength compared to placebo in the acute treatment of migraine. The data revealed that both...

Lees hier de meest recente artikelen uit de farma

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl